• Licensing and supervision
    • Brexit
    • Licensing of medicines
    • Authorisation procedures
    • Company authorisations and registrations
    • Supervision and inspection
    • Clinical trials
    • How to evaluate evidence of the efficacy of medicines
    • Evaluation of reviews
    • Report suspected illegal activities
    • Falsified medicines
    • Compassionate use
    • Medicine or not
    • Export certificates
    • Fees
    • Name/address changes
    • Relationships
    • Financial support
    • Medicinal Products Committee
    • Publications
  • Side effects and product information
    • Side effects of medicines
    • Additional monitoring
    • News on pharmacovigilance
    • Biological and biosimilar medicinal products
    • Safety updates
    • Post Authorisation Safety Study
    • Direct Healthcare Professional Communication
    • Adverse events
    • Drug interaction
    • Pharmacovigilance Council
    • Find medicines
    • Publications
  • Reimbursement and prices
    • General reimbursement
    • Individual reimbursement
    • Reimbursement thresholds
    • Medicines bought in another EU/EEA country
    • Reimbursement Committee
    • The EU HTA regulation
    • Prices of medicines
    • Product numbers
    • Central Reimbursement Register
    • Reimbursable nutritional products
    • Publications
  • Pharmacies and sale of medicines
    • Pharmacies
    • Sale outside pharmacies
    • Over-the-counter medicines
    • Substitution
    • Medicines imported from abroad
    • Buying and selling medicines online
    • Sale of medicines or food supplements online
    • Doctors buying medicines for use in their own practices
    • Report suspected illegal sale of medicines
    • Prescriptions from another country
    • Publications
  • Medical devices
    • Incident reporting
    • New regulations
    • COVID-19 antigen test for self-test
    • Advice to consumers on buying face masks
    • New Tech – new technological possibilities and medical devices
    • Interruption or discontinuation of the supply of medical devices
    • Patient safety and safe medical devices
    • Development of medical devices
    • Regulatory advice for medical device companies
    • CE marking
    • Notified bodies
    • Registration and marketing
    • Clinical investigations
    • Performance studies of in vitro diagnostic medical devices (IVDs)
    • Certificates of Free Sale
    • Legislation and guidance
    • Publications
  • Special product areas
    • Veterinary medicines
    • Natural medicinal products and vitamin and mineral products
    • Euphoriant substances
    • Medical gases
    • Radiopharmaceuticals
    • Medicines affecting the ability to drive
    • Medicinal cannabis
    • Regulation of innovative medicinal products including ATMP
  • About us
    • Mission, vision and strategy
    • Contact
    • Organisation
    • Whistleblowing scheme of the Danish Medicines Agency
    • The Danish Medicines Agency funding
    • Management of conflicts of interest
    • Transparency in the Danish Medicines Agency
    • Data protection policy
    • Targets and tasks
    • International collaboration
    • Jobs
    • Digital services
    • About this site
    • Social media
    • Design
    • Campaigns
    • Copyright
    • Cookies
    • Publications
    • Sitemap
  • News
    • Subscribe to news
    • Edit subscription
    • Unsubscribe
    • News categories
    • Themes
    • Our newsletter DKMA Update
    • RSS Feed
    • 2025
  • Publications
    • Order publications
    • 2025
    • 2024
    • 2023
    • 2022
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
    • 2011
    • 2010
    • 2009
    • 2008
    • 2007
    • 2006
Go to main content
  • News
  • About us
  • Contact us
  • Publications
  • Cookies
  • Licensing and supervision
    • Brexit
    • Licensing of medicines
    • Authorisation procedures
    • Company authorisations and registrations
    • Supervision and inspection
    • Clinical trials
    • How to evaluate evidence of the efficacy of medicines
    • Evaluation of reviews
    • Report suspected illegal activities
    • Falsified medicines
    • Compassionate use
    • Medicine or not
    • Export certificates
    • Fees
    • Name/address changes
    • Relationships
    • Financial support
    • Medicinal Products Committee
    • Publications
  • Side effects and product information
    • Side effects of medicines
    • Additional monitoring
    • News on pharmacovigilance
    • Biological and biosimilar medicinal products
    • Safety updates
    • Post Authorisation Safety Study
    • Direct Healthcare Professional Communication
    • Adverse events
    • Drug interaction
    • Pharmacovigilance Council
    • Find medicines
    • Publications
  • Reimbursement and prices
    • General reimbursement
    • Individual reimbursement
    • Reimbursement thresholds
    • Medicines bought in another EU/EEA country
    • Reimbursement Committee
    • The EU HTA regulation
    • Prices of medicines
    • Product numbers
    • Central Reimbursement Register
    • Reimbursable nutritional products
    • Publications
  • Pharmacies and sale of medicines
    • Pharmacies
    • Sale outside pharmacies
    • Over-the-counter medicines
    • Substitution
    • Medicines imported from abroad
    • Buying and selling medicines online
    • Sale of medicines or food supplements online
    • Doctors buying medicines for use in their own practices
    • Report suspected illegal sale of medicines
    • Prescriptions from another country
    • Publications
  • Medical devices
    • Incident reporting
    • New regulations
    • COVID-19 antigen test for self-test
    • Advice to consumers on buying face masks
    • New Tech – new technological possibilities and medical devices
    • Interruption or discontinuation of the supply of medical devices
    • Patient safety and safe medical devices
    • Development of medical devices
    • Regulatory advice for medical device companies
    • CE marking
    • Notified bodies
    • Registration and marketing
    • Clinical investigations
    • Performance studies of in vitro diagnostic medical devices (IVDs)
    • Certificates of Free Sale
    • Legislation and guidance
    • Publications
  • Special product areas
    • Veterinary medicines
    • Natural medicinal products and vitamin and mineral products
    • Euphoriant substances
    • Medical gases
    • Radiopharmaceuticals
    • Medicines affecting the ability to drive
    • Medicinal cannabis
    • Regulation of innovative medicinal products including ATMP
2016
News / 2016
News

You must accept marketing cookies to share the page by mail

Update consent

Share by mail

Verify you are a human

...

  • Danish Pharmacovigilance Update, 26 September 2013

    | 21 November 2013 |

    In this issue of Danish Pharmacovigilance Update: Filgrastim (Neupogen) and pegfilgrastim (Neulasta) are associated with risk of capillary leak syndrome.

  • Danish Pharmacovigilance Update, 29 August 2013

    | 23 October 2013 |

    In this issue of Danish Pharmacovigilance Update: Cases of acquired haemophilia following treatment with clopidogrel (Plavix® etc.)

  • Danish Pharmacovigilance Update, 27 June 2013

    | 24 July 2013 |

    In this issue of Danish Pharmacovigilance Update: The benefits of medicines for the treatment of acne (Diane® Mite and others) continue to outweigh the risks of use within the indication.

  • Voluntary Harmonisation Procedure (VHP) for the assessment of multinational clinical trial applications

    | 09 July 2013 |

    The Voluntary Harmonisation Procedure is a procedure which makes it possible to obtain a coordinated assessment of an application for a clinical trial that is to take place in several European countries.

  • Danish Pharmacovigilance Update, 23 May 2013

    | 17 June 2013 |

    In this issue of Danish Pharmacovigilance Update: Cases of necrotising fasciitis associated with the use of bevacizumab (Avastin®).

  • Danish Pharmacovigilance Update, 25 April 2013

    | 29 May 2013 |

    In this issue of Danish Pharmacovigilance Update: Cerebral haemorrhage in association with the use of methylphenidate (Ritalin® etc.).

  • Painkillers to be prescription only in Denmark from 30 September 2013

    | 28 May 2013 |

    The Danish Health and Medicines Authority has decided that large packs of mild painkillers will be prescription-only in Denmark from 30 September 2013. From this date, it will only be possible to buy small packs of mild painkillers over the counter. There will be no changes to dispensing status of the medicines that can be bought over the counter after 30 September.

  • Danish Pharmacovigilance Update, 21 March 2013

    | 25 April 2013 |

    In this issue of Danish Pharmacovigilance Update: Depressive and suicidal thoughts following discontinuation of varenicline (Champix®).

  • Danish Pharmacovigilance Update, 21 February 2013

    | 25 April 2013 |

    In this issue of Danish Pharmacovigilance Update: Cardiovascular monitoring when initiating and re-initiating treatment with fingolimod (Gilenya®).

  • Painkillers to be prescription only in Denmark

    | 08 April 2013 |

    In Denmark, it will soon only be possible to buy large packs of mild painkillers when prescribed by a doctor. The aim is to reduce poisoning incidents and the need for liver transplants.

  • Danish Pharmacovigilance Update, 17 January 2013

    | 26 March 2013 |

    In this issue of Danish Pharmacovigilance Update: The Pharmacovigilance Risk Assessment Committee, PRAC, finds that the risks outweigh the benefits from the use of Tredaptive®

All items (479)
  • Time

    • 2025 (10)
    • 2024 (26)
    • 2023 (24)
    • 2022 (20)
    • 2021 (44)
    • 2020 (62)
    • 2019 (20)
    • 2018 (37)
    • 2017 (54)
    • 2016 (53)
    • 2015 (11)
    • 2014 (13)
    • 2013 (11)
      • November (1)
      • October (1)
      • July (2)
      • June (1)
      • May (2)
      • April (3)
      • March (1)
    • 2012 (11)
    • 2011 (13)
    • 2010 (9)
    • 2009 (14)
    • 2008 (7)
    • 2007 (3)
    • 2006 (10)
footer-logo

Danish Medicines Agency

Axel Heides Gade 1

2300 København S

Email: dkma@dkma.dk


The Danish Medicines Agency is part of the
Ministry of Interior and Health.

Contact the Danish Medicines Agency

+45 44 88 95 95 (9am - 3pm)

Follow us

  • facebook logo
  • LinkedIn
  • RSS

CVR-nr. 37 05 24 85

EAN 5798 000 36 33 66

Privacy policy Cookie policy